Compare Smith & Nephew plc (SNN) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Invesco S&P 500 Momentum ETF — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Invesco S&P 500 Momentum ETF trades at $152 (market cap $23.48B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 2.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| SNN | SPMO | |
|---|---|---|
Market Cap | $11.10B | $23.48B |
Volume | 1,051,703 | 1,876,152 |
Sector | Health | Broad Market / Factor |
52-Week High | $37.17 | $161.66 |
52-Week Low | $26.42 | $107.84 |
Typical Hold Time | 120 Days | 54 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
SPMO trades at $153.00 with minimal daily movement (+0.01%). The ETF maintains a bullish technical stance with strong moving average signals, though oscillators show neutral momentum. Recent portfolio rebalancing added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest grew with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
SPMO offers concentrated exposure to S&P 500 momentum leaders with historical outperformance. Key risks include sector concentration in technology and semiconductors, plus higher volatility than the broader market. The fund's momentum strategy faces challenges during market rotations but maintains structural advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
